With these in the background, we aimed to investigate the effect of the presence of vessel and pericyte density, and VEGFA and CSPG4 expressions in the tumor tissue, on the efficacy of the bevacizumab in metastatic or recurrent colorectal cancer patients. The gene discussed is VEGFA; the disease is neoplasm.